TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02704221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit activity tracker
Description: Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary rewards
Description: Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT training sessions
Description: Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BPT training sessions
Description: Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
Study: NCT03179592

Intervention type: DRUG
Intervention: Ultravist 370Mg I/Ml Solution for Injection
Description: Reduced contrast-volume injection protocols based on patient specific tube voltage.
Study: NCT00285974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
Description: metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
Study: NCT00652431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vytorin + Niaspan
Description: Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vytorin
Description: Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niaspan
Description: Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
Study: NCT02366663

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90-Yttrium Ibritumomab tiuxetan
Description: 0.4 mCi/kg given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplant
Description: Autologous Hematopoietic Stem Cell Transplantation (ASCT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplant
Description: Autologous Hematopoietic Stem Cell Transplantation (ASCT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT03095352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
Study: NCT04020380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250Mg Capsule
Description: 250 mg OD
Study: NCT04998903

Intervention type: PROCEDURE
Intervention: Fiberoptic Bronchoscopy
Description: Fiberoptic bronchoscopy done under conscious sedation
Study: NCT01259856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS
Description: The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
Study: NCT02731391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor reconstruction（with or without mesh）

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor reconstruction（with or without mesh）
Study: NCT02065310

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)
Description: Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 \& 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications.
Study: NCT01860534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye covers
Description: The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
Study: NCT03095352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: For HER2+ patients: IV every 3 weeks using standard approved dosing
Study: NCT04405505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel for Injection (albumin bound)
Description: a anti-microtubule drug.
Study: NCT02080689

Intervention type: OTHER
Group type: OTHER
Intervention: Decipher

Intervention type: OTHER
Group type: OTHER
Intervention: Decipher
Study: NCT01665755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upstroke Compression Defibrillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precompression Defibrillation
Study: NCT00685620

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reinforcement Based Treatment
Description: 3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement Based Treatment
Description: 3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
Study: NCT01504854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
Study: NCT02356406

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Radiosurgery
Description: 5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis.
Study: NCT01510808

Intervention type: PROCEDURE
Intervention: orthodontic treatment
Description: Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.

Intervention type: PROCEDURE
Intervention: orthodontic treatment
Description: Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
Study: NCT02003560

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation
Description: 9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
Study: NCT01702363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
Study: NCT00946530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Participants uses bright light

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants uses dim light
Study: NCT03349541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Care Curriculum
Description: A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations.
Study: NCT03095352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: For HER2+ patients: IV every 3 weeks using standard approved dosing
Study: NCT00118482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fludrocortisone acetate
Description: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludrocortisone acetate
Description: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
Study: NCT01152008

Intervention type: OTHER
Intervention: tourniquet ischemia
Description: Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
Study: NCT03934892

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lactate
Description: check lactate levels during cardiopulmonary bypass in adult cardiac operations
Study: NCT04072861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-9
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-9
Description: intravenous administration
Study: NCT04204720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle (Chiba)
Description: intravascular injection using chiba needle during caudal epidural block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle (Whitacre)
Description: intravascular injection using whitacre needle during caudal epidural block
Study: NCT04072861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-9
Description: intravenous administration
Study: NCT04611295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teleneurological evaluation and support
Description: The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
Study: NCT01884636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: oral
Study: NCT03566186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).

Intervention type: OTHER
Group type: OTHER
Intervention: Passive recovery
Description: Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
Study: NCT03043638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+ADM+PRP
Description: CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+ADM
Description: CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
Study: NCT01607372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
Study: NCT02125487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching using Hybrid Simulation of breast examination
Description: Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching using traditional method
Description: Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE.
Study: NCT03056495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-hydroxy-N'-phenyl-octanediamide (Vorinostat)
Description: N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
Study: NCT01633996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
Study: NCT00646971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP device
Description: for 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo device
Description: for 4 weeks
Study: NCT01607372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type 1 amber glass bottle
Description: fitted with a metered Valios VP7 pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type 1 amber glass bottle
Description: fitted with a metered Valios VP7 pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type 1 amber glass bottle
Description: fitted with a metered Valios VP7 pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type 1 amber glass bottle
Description: fitted with a metered Valios VP7 pump

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As for GSK2245035 nasal spray solution except for omission of the active ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As for GSK2245035 nasal spray solution except for omission of the active ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As for GSK2245035 nasal spray solution except for omission of the active ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As for GSK2245035 nasal spray solution except for omission of the active ingredient
Study: NCT04656886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Infusion
Study: NCT04128423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMV564
Description: AMV564 will be administered daily
Study: NCT00240630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sumatriptan succinate/naproxen sodium
Description: Combination Tablet of Treximet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo to match
Study: NCT00446485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba standardized extract 24/6
Description: tablets, 120 mg/day (60 mg two times daily) during 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba standardized extract 24/6
Description: tablets, 60 mg/day during 6 months
Study: NCT01901692

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE+External beam RT
Description: Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
Study: NCT03040596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard voice therapy
Description: Standard voice therapy sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard voice therapy
Description: Standard voice therapy sessions
Study: NCT02222740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)
Description: Schedule II Class

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)
Description: Schedule II Class
Study: NCT00446485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo during 6 months
Study: NCT01744509

Intervention type: DEVICE
Group type: OTHER
Intervention: Capsule colonoscopy;
Description: All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
Study: NCT03361319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vargatef
Description: small molecule triple kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vargatef
Description: small molecule triple kinase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vargatef
Description: small molecule triple kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Paclitaxel formulated as albumin bound nanoparticles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Paclitaxel formulated as albumin bound nanoparticles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abraxane
Description: Paclitaxel formulated as albumin bound nanoparticles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo in place of Ninedanib
Study: NCT01941563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Condoliase
Description: 1.25U, intradiscal injection, one time

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Study: NCT01717677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical prostatectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: percutaneous radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: permanent seed implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Surveillance